Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management

A coordinated, multidisciplinary approach to care is essential for optimum management of the primary manifestations and secondary complications of Duchenne muscular dystrophy (DMD). Contemporary care has been shaped by the availability of more sensitive diagnostic techniques and the earlier use of therapeutic interventions, which have the potential to improve patients' duration and quality of life. In part 2 of this update of the DMD care considerations, we present the latest recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and surgical management for boys and men with DMD. Additionally, we provide guidance on cardiac management for female carriers of a disease-causing mutation. The new care considerations acknowledge the effects of long-term glucocorticoid use on the natural history of DMD, and the need for care guidance across the lifespan as patients live longer. The management of DMD looks set to change substantially as new genetic and molecular therapies become available.

[1]  R. Szczesniak,et al.  Sleep disordered breathing in young boys with Duchenne muscular dystrophy. , 2015, The Journal of pediatrics.

[2]  C. Larson,et al.  Bone mineral density and fractures in boys with Duchenne muscular dystrophy. , 2000, Journal of pediatric orthopedics.

[3]  L. M. Sutherland,et al.  The effect of posterior spinal fusion on respiratory function in Duchenne muscular dystrophy , 2013, European Spine Journal.

[4]  S. Taback,et al.  High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Vivegnis,et al.  Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. , 2005, Acta orthopaedica Belgica.

[6]  P. Lascombes,et al.  Flexible intramedullary nailing for distal femoral fractures in patients with myopathies , 2012, Journal of children's orthopaedics.

[7]  B. Alman,et al.  Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. , 2013, The Journal of bone and joint surgery. American volume.

[8]  J. Pépin,et al.  Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[9]  R. Engelbert,et al.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study , 2004, The Lancet.

[10]  J. Bach,et al.  Prevention of pulmonary morbidity for patients with neuromuscular disease. , 2000, Chest.

[11]  T. Miura,et al.  Duchenne muscular dystrophy: Survival by cardio-respiratory interventions , 2011, Neuromuscular Disorders.

[12]  J. Bach,et al.  Active lung volume recruitment to preserve vital capacity in Duchenne muscular dystrophy. , 2017, Journal of rehabilitation medicine.

[13]  A. Amodeo,et al.  Left ventricular assist device in Duchenne cardiomyopathy: can we change the natural history of cardiac disease? , 2012, International journal of cardiology.

[14]  S. Raman,et al.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial , 2015, The Lancet Neurology.

[15]  Robert G. Miller,et al.  A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non‐invasive ventilation in amyotrophic lateral sclerosis , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[16]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[17]  S. Ohtori,et al.  Surgical management of severe scoliosis with high risk pulmonary dysfunction in Duchenne muscular dystrophy: patient function, quality of life and satisfaction , 2010, International Orthopaedics.

[18]  L. Cripe,et al.  Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy , 2013, Paediatric anaesthesia.

[19]  H. Roper,et al.  Duchenne muscular dystrophy: the management of scoliosis. , 2016, Journal of spine surgery.

[20]  B. Fauroux,et al.  Long term continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV) in children: Initiation criteria in real life , 2016, Pediatric pulmonology.

[21]  N. Crabtree,et al.  Vertebral fractures assessment in children: Evaluation of DXA imaging versus conventional spine radiography. , 2017, Bone.

[22]  D. Hillman,et al.  Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. , 2000, American journal of respiratory and critical care medicine.

[23]  E. Hoffman,et al.  Contemporary Cardiac Issues in Duchenne Muscular Dystrophy , 2015, Circulation.

[24]  J. Jaremko,et al.  Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. , 2015, The Journal of clinical endocrinology and metabolism.

[25]  P. Calverley,et al.  Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. , 2001, American journal of respiratory and critical care medicine.

[26]  S. Raman,et al.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial , 2017, Orphanet Journal of Rare Diseases.

[27]  M. Taylor,et al.  Myocardial Fibrosis and Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Carriers Using Cardiac Magnetic Resonance Imaging , 2015, Pediatric Cardiology.

[28]  Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. , 1999, Chest.

[29]  J. Benditt,et al.  The American College of Chest Physicians Consensus Statement on the Respiratory and Related Management of Patients With Duchenne Muscular Dystrophy Undergoing Anesthesia or Sedation* , 2009, Pediatrics.

[30]  H. Domené,et al.  Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation , 2000, Pediatric Nephrology.

[31]  J. Kanis,et al.  Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures , 2013, Osteoporosis International.

[32]  Hanns Lochmüller,et al.  Adult care for Duchenne muscular dystrophy in the UK , 2014, Journal of Neurology.

[33]  Paola Baiardi,et al.  Cough Peak Flows: Standard Values for Children and Adolescents , 2008, American journal of physical medicine & rehabilitation.

[34]  J. Stypmann,et al.  Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study. , 2016, European heart journal cardiovascular Imaging.

[35]  B. Zemel,et al.  Revised Pediatric Reference Data for the Lateral Distal Femur Measured by Hologic Discovery/Delphi Dual Energy X-Ray Absorptiometry , 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[36]  Colin Chandler,et al.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation , 2002, Neuromuscular Disorders.

[37]  H. Wong,et al.  Long-term Follow-up of Pulmonary Function and Scoliosis in Patients With Duchenne’s Muscular Dystrophy and Spinal Muscular Atrophy , 2015, Journal of pediatric orthopedics.

[38]  F. Glorieux,et al.  Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo‐Controlled Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  N. Barrowman,et al.  Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy. , 2012, Archives of physical medicine and rehabilitation.

[40]  L. Bachrach Diagnosis and treatment of pediatric osteoporosis , 2014, Current opinion in endocrinology, diabetes, and obesity.

[41]  L. Tatò,et al.  Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  J. Bach,et al.  Indicators for ventilator use in Duchenne muscular dystrophy. , 2011, Respiratory medicine.

[43]  M. Toussaint,et al.  Lung function accurately predicts hypercapnia in patients with Duchenne muscular dystrophy. , 2007, Chest.

[44]  H. Nagaraja,et al.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy , 2007, Neurology.

[45]  D. Moher,et al.  Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study , 2012, Arthritis care & research.

[46]  H. Panitch,et al.  Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. , 2004, Chest.

[47]  B. Lentle,et al.  The time to and determinants of first fractures in boys with Duchenne muscular dystrophy , 2017, Osteoporosis International.

[48]  S. Houde,et al.  Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. , 2008, Pediatric neurology.

[49]  N. Barrowman,et al.  Respiratory management strategies for Duchenne muscular dystrophy: practice variation amongst canadian sub‐specialists , 2013, Pediatric pulmonology.

[50]  Caleb J. Behrend,et al.  Fat embolism syndrome in patients with Duchenne muscular dystrophy , 2013, Neurology.

[51]  L. Ward,et al.  The management of osteoporosis in children , 2016, Osteoporosis International.

[52]  B. Bissonnette,et al.  Duchenne muscular dystrophy: an old anesthesia problem revisited , 2007, Paediatric anaesthesia.

[53]  H. Bécane,et al.  Ventricular arrhythmia in Duchenne muscular dystrophy: Prevalence, significance and prognosis , 1993, Neuromuscular Disorders.

[54]  A. Green,et al.  The Duchenne muscular dystrophy population in Denmark, 1977–2001: prevalence, incidence and survival in relation to the introduction of ventilator use , 2003, Neuromuscular Disorders.

[55]  J. Bach,et al.  Duchenne Muscular Dystrophy: Prolongation of Life by Noninvasive Ventilation and Mechanically Assisted Coughing , 2002, American journal of physical medicine & rehabilitation.

[56]  J. Jaremko,et al.  Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  A. Amodeo,et al.  Implantation of a left ventricular assist device as a destination therapy in Duchenne muscular dystrophy patients with end stage cardiac failure: Management and lessons learned , 2015, Neuromuscular Disorders.

[58]  David Gozal,et al.  Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. , 2004, American journal of respiratory and critical care medicine.

[59]  Y. Rideau,et al.  Respiratory function in the muscular dystrophies , 1981, Muscle & nerve.

[60]  Christopher E. Buller,et al.  AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy : Executive summary , 2011 .

[61]  M. Nevitt,et al.  Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  A. McCormick,et al.  The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy , 2012, Osteoporosis International.

[63]  F. Lofaso,et al.  Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders , 2011, European Respiratory Journal.

[64]  H. Jasper,et al.  Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients , 2007, Pediatric Nephrology.

[65]  H. Topaloglu,et al.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy , 2016, Neurology.

[66]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[67]  J. Bach,et al.  ORIGINAL RESEARCHCRITICAL CARE MEDICINEExtubation of Patients With Neuromuscular Weakness: A New Management Paradigm , 2010 .

[68]  S. Moon,et al.  Functional outcomes in Duchenne muscular dystrophy scoliosis: comparison of the differences between surgical and nonsurgical treatment. , 2014, The Journal of bone and joint surgery. American volume.

[69]  Barry J Maron,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[70]  Jes Rahbek,et al.  206th ENMC International Workshop: Care for a novel group of patients – adults with Duchenne muscular dystrophy Naarden, The Netherlands, 23–25 May 2014 , 2015, Neuromuscular Disorders.

[71]  K. Wollinsky,et al.  Long-term ventilation of patients with Duchenne muscular dystrophy: experiences at the Neuromuscular Centre Ulm , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[72]  M. Bouxsein,et al.  Biomechanics of Vertebral Fractures and the Vertebral Fracture Cascade , 2010, Current osteoporosis reports.

[73]  S. Söderhäll,et al.  Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta , 2006, Archives of Disease in Childhood.

[74]  L. McAdam,et al.  Fat Embolism Syndrome following minor trauma in Duchenne muscular dystrophy , 2012, Neuromuscular Disorders.

[75]  J. Finsterer,et al.  Treatment of dystrophin cardiomyopathies , 2014, Nature Reviews Cardiology.

[76]  Craig McDonald,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care , 2010, The Lancet Neurology.

[77]  N. Bishop,et al.  Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. , 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[78]  Munish C. Gupta,et al.  The Natural History of Cardiac and Pulmonary Function Decline in Patients With Duchenne Muscular Dystrophy , 2011, Spine.

[79]  A. Simonds,et al.  British Thoracic Society guideline for respiratory management of children with neuromuscular weakness , 2012, Thorax.

[80]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[81]  B. Wong,et al.  Implantation of the HeartMate II and HeartWare Left Ventricular Assist Devices in Patients With Duchenne Muscular Dystrophy: Lessons Learned From the First Applications , 2014, ASAIO journal.

[82]  H. Levison,et al.  Cough capacity in patients with muscular dystrophy. , 1988, Chest.

[83]  F. Glorieux,et al.  Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[84]  E. Mercuri,et al.  Fracture prevalence in Duchenne muscular dystrophy. , 2002, Developmental medicine and child neurology.

[85]  N. Barrowman,et al.  Long-Term Effects of Lung Volume Recruitment on Maximal Inspiratory Capacity and Vital Capacity in Duchenne Muscular Dystrophy. , 2016, Annals of the American Thoracic Society.

[86]  The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. , 2015, The Journal of clinical endocrinology and metabolism.

[87]  R. Finkel,et al.  Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. , 2017, Contemporary clinical trials.

[88]  M. Mhanna,et al.  Cardiac phenotype determines survival in Duchenne muscular dystrophy , 2016, Pediatric pulmonology.

[89]  A. Vianello,et al.  Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy , 1996, Neuromuscular Disorders.

[90]  D. Reid,et al.  Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. , 1991, Pediatrics.

[91]  M. Benton,et al.  Characterization of pulmonary function in Duchenne Muscular Dystrophy , 2015, Pediatric pulmonology.

[92]  A. Aliverti,et al.  Determinants of cough efficiency in Duchenne muscular dystrophy , 2014, Pediatric pulmonology.

[93]  O. Mäkitie,et al.  Low bone mass in patients with motor disability: prevalence and risk factors in 59 Finnish children , 2010, Developmental medicine and child neurology.

[94]  J. Bach,et al.  The respiratory management of patients with duchenne muscular dystrophy: A DMD care considerations working group specialty article , 2010, Pediatric pulmonology.

[95]  E. McNally New approaches in the therapy of cardiomyopathy in muscular dystrophy. , 2007, Annual review of medicine.

[96]  J. Bach,et al.  Duchenne Muscular Dystrophy: Continuous Noninvasive Ventilatory Support Prolongs Survival , 2011, Respiratory Care.

[97]  J. Bach,et al.  Changing Trends in the Management of End-Stage Neuromuscular Respiratory Muscle Failure: Recommendations of an International Consensus , 2013, American journal of physical medicine & rehabilitation.

[98]  A. Aliverti,et al.  Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options , 2015, Therapeutics and clinical risk management.

[99]  A. Woolnough,et al.  Twenty-four hour noninvasive ventilation in Duchenne muscular dystrophy: a safe alternative to tracheostomy. , 2013, Canadian respiratory journal.

[100]  E. Marchiori,et al.  Fat embolism syndrome: State-of-the-art review focused on pulmonary imaging findings. , 2016, Respiratory medicine.

[101]  A. Toutain,et al.  Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. , 2007, American heart journal.

[102]  J. Bach,et al.  Nocturnal oxygenation and prognosis in Duchenne muscular dystrophy. , 2000, American journal of respiratory and critical care medicine.

[103]  S. Adami,et al.  Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. , 2006, The Journal of pediatrics.

[104]  U. Schara,et al.  Mechanical insufflation/exsufflation improves vital capacity in neuromuscular disorders , 2015, Chronic respiratory disease.

[105]  C. Reilly,et al.  Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort , 2016, Journal of pediatric orthopedics.